Giredestrant and SERDs: What Concierge Practices Need to Know

The Shifting Landscape of Breast Cancer Treatments

This week, during the San Antonio Breast Cancer Symposium, Eleonora Teplinsky, MD, illuminated critical insights on the lidERA trial that assessed giredestrant, a promising oral selective estrogen receptor degrader (SERD), compared to standard chemotherapy options for early-stage, hormone receptor-positive, HER2-negative breast cancer. The results spark questions about future treatments and how they might transform the care landscape for patients.

Understanding Giredestrant and its Role

Giredestrant targets and degrades estrogen receptors, which are crucial in the growth of hormone receptor-positive breast cancer cells. In the trial, over 4,170 patients were involved, with a promising outcome of significantly improved invasive disease-free survival (iDFS) compared to current treatments like tamoxifen and aromatase inhibitors. This is particularly relevant as hormone receptor-positive breast cancer accounts for about 70% of cases, emphasizing the need for effective therapies during the early stages.

Equalizing Access to Advance Care

As a concierge medical practice owner, recognizing cutting-edge treatments like giredestrant can set you apart by enhancing your connection with patients. Highlighting treatments that offer less invasive options and improved quality of life resonates deeply with your clients, many of whom seek a comprehensive, progressive approach to their health.

Impact on Patient Care and Connections

Patient engagement is crucial in concierge medicine, and being informed about innovative treatments fosters deeper relationships. Transitioning conversations from traditional treatments to new options like giredestrant can help patients feel more invested and reassured about their care. It creates a platform for dialogue about treatment choices, allowing patients to share their feelings and preferences, ensuring they are part of their care journey.

Future Outlook and Preparing for Changes

Looking ahead, Teplinsky emphasized that as more SERD trials yield results, the standard of endocrine therapy might evolve. This underlines the importance of staying abreast of clinical trial developments and emerging therapies to maintain a competitive edge in your practice. Incorporating such discussions into your patient interactions could not only enhance care but also position your practice as a forward-thinking leader in breast cancer treatment.

Join the Conversation

The conversation surrounding breast cancer treatments is evolving, and understanding these developments will empower your practice. Connect with your patients about the potential benefits of emerging therapies like giredestrant, and enhance their trust in your commitment to their health. Continuous learning about breakthroughs in treatment creates an opportunity to reaffirm your role as a dedicated partner in health care.